Literature DB >> 21372398

Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.

Yoshihiko Shibayama1, Kou Nakano, Hiroshi Maeda, Miyuki Taguchi, Ryuji Ikeda, Mitsuru Sugawara, Ken Iseki, Yasuo Takeda, Katsushi Yamada.   

Abstract

Sorafenib and sunitinib is a small molecule inhibitor of certain receptor tyrosine kinases, and have improved outcomes for patients with advanced renal cell carcinoma. Inhibitory concentration of 50% cell growth of sorafenib significantly rose to 6.4-fold in a multidrug resistance protein 2 (MRP2) transfected cell line versus control cell line. The concentration of sorafenib was significantly decreased to 74% of control cells after 3 h treatment. In contrast, a tyrosine kinase inhibitor sunitinib did not show alteration of inhibitory concentration of 50% cell growth and accumulation into the cells of MRP2 transfected cells. The present study suggest that sorafenib is a substrate for MRP2, suggesting that MRP2 may implicate drug resistance to sorafenib.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21372398     DOI： 10.1248/bpb.34.433

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN： 0918-6158            Impact factor:   2.233


  19 in total

1.  A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule.

Authors:  Zu-long Liu; Wei Tian; Yong Wang; Shan Kuang; Xiao-min Luo; Qiang Yu
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 3.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.

Authors:  K Mandery; H Glaeser; M F Fromm
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.

Authors:  Makito Miyake; Satoshi Anai; Kiyohide Fujimoto; Sayuri Ohnishi; Masaomi Kuwada; Yasushi Nakai; Takeshi Inoue; Atsushi Tomioka; Nobumichi Tanaka; Yoshihiko Hirao
Journal:  Oncol Lett       Date:  2012-03-29       Impact factor: 2.967

5.  Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.

Authors:  Brandon Swift; Noelia Nebot; Jin Kyung Lee; Tianxiang Han; William R Proctor; Dhiren R Thakker; Dieter Lang; Martin Radtke; Mark J Gnoth; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-03-12       Impact factor: 3.922

6.  Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma.

Authors:  Bo Zhai; Xue-Ying Sun
Journal:  World J Hepatol       Date:  2013-07-27

7.  Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7).

Authors:  Ekaterina V Malofeeva; Natalya Domanitskaya; Mariya Gudima; Elizabeth A Hopper-Borge
Journal:  Cancer Res       Date:  2012-10-19       Impact factor: 12.701

Review 8.  Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.

Authors:  Peter Makhov; Shreyas Joshi; Pooja Ghatalia; Alexander Kutikov; Robert G Uzzo; Vladimir M Kolenko
Journal:  Mol Cancer Ther       Date:  2018-07       Impact factor: 6.261

9.  Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

Authors:  Aksana Vasilyeva; Selvi Durmus; Lie Li; Els Wagenaar; Shuiying Hu; Alice A Gibson; John C Panetta; Sridhar Mani; Alex Sparreboom; Sharyn D Baker; Alfred H Schinkel
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

Review 10.  Reversing multidrug resistance by tyrosine kinase inhibitors.

Authors:  Miao He; Min-Jie Wei
Journal:  Chin J Cancer       Date:  2012-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.